Editors-in-Chief

NameInstituteCity
Wen, Yumei Shanghai Medical College, Fudan University Shanghai
Lu, Shan University of Massachusetts Medical School Worcester

Yu-Mei Wen

MD, founder and professor of Institute of Medical Microbiology, Fudan University, China and Professor of Key Laboratory of Medical Molecular Virology, Ministry of Education/Ministry of Health. Her research interests are in molecular virology and immunology of hepatitis B virus, and in microbial functional genomic studies. She is one of the pioneers in developing therapeutic vaccine for chronic hepatitis B patients. Prof. Wen graduated from Shanghai Medical University and has been a WHO fellow at London School of Hygiene and Tropical Medicine, and Fogarty visiting scholar at NIAID, National Institutes of Health, USA. She has published 240 articles home and abroad, and has edited and co-edited 8 books, including Viral Hepatitis in China-Problems and Control Strategies (Karger publisher, 1992) and recent works on micorbes and infections in China (World Scientific Publisher, 2010). She was acting editor of Archives of Virology (2008-2011) and has served as reviewer for PloS One, J Med Virology, Vaccine etc.

Shan Lu

MD, PhD, MHA, is a physician scientist and a leader in novel vaccine research including vaccines against emerging infectious diseases. Currently he is Head of Laboratory of Nucleic Acid Vaccines and professor of Departments of Medicine, Biochemistry and Molecular Pharmacology at the University of Massachusetts Medical School (UMMS), Worcester, Massachusetts, USA. He is also UMMS' co-director of Center for AIDS Research (CFAR) and Associate Director of Medicine Residency Program. He holds adjunct faculty appointment at several Chinese academic institutions and is an Executive Board member of China AIDS Vaccine Initiative (CAVI). He is the current president of International Society for Vaccines (ISV) and served as the co-chair for the 2nd to 6th Vaccine and ISV Annual Global Congresses. Dr. Lu's research focuses on the induction of protective antibody responses by novel vaccination strategies with funding support from the US NIH and the Gates Foundation. His team conducted world's first DNA prime-protein boost HIV-1 vaccine clinical trial and elicited cross-reactive neutralizing antibody responses in humans - a major progress in AIDS vaccine development.